No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALGS Aligos Therapeutics
- 0.829
- +0.005+0.66%
Close Apr 24 16:00 ET
- 0.820
- -0.009-1.04%
Post 18:08 ET
62.73MMarket Cap-609P/E (TTM)
0.870High0.790Low644.25KVolume0.815Open0.824Pre Close538.70KTurnover1.76%Turnover RatioLossP/E (Static)75.67MShares1.38052wk High0.68P/B30.41MFloat Cap0.53952wk Low--Dividend TTM36.68MShs Float37.510Historical High--Div YieldTTM9.75%Amplitude0.539Historical Low0.836Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutic
Express News | Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada's CADTH
Express News | Earlier Announced, Aligos Therapeutics Has Been Awarded A $1.3M NIH Contract To Conduct Clinical Development Of A Compound For The Treatment Of Covid-19
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 From ALG-055009 and ALG-000184 Phase 1 Studies
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutic
Express News | Aligos Therapeutics Announces Initiation Of Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
Comments
Update
$Aligos Therapeutics(ALGS.US$ Mirum’s LIVMARLI receives positive reimbursement recommendation by Canada’s CADTH
Aligos Therapeutics' P/S ratio remains below industry median due to poor revenue outlook. Without significant change, a drastic stock price rise is unlikely. The low P/S ratio is justified by inferior revenue forecasts.
The company anticipates the new appointments to be beneficial as they advance towards significant clinical data and strategically expand their team for Aligos' next growth phase. Both Tarazi and Aneja are thrilled to contribute to Aligos' mission in treating liver and viral diseases.
1
$Aligos Therapeutics(ALGS.US$ Ah! Phase one results coming here directly! Still if playing secure profits when presented 
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg